USPH Acquires 50% Stake in 50 PT Clinics in New York

U.S. Physical Therapy, Inc. (USPH) has successfully concluded the acquisition of a 50% equity interest in a management services organization that oversees 50 outpatient physical therapy clinics, predominantly located in New York. This move reflects USPH's strategic plans to expand its presence in New York and neighboring states. The clinics managed by the acquired organization offer physical, occupational, and speech therapy services both on-site and in patients' homes. The consolidated annual revenue generated by these clinics stands at approximately $64.0 million, with an annual EBITDA of around $12.0 million.

As of 2024, U.S. Physical Therapy, Inc. owns and/or manages a total of 750 outpatient physical therapy clinics spanning 43 states. These clinics cater to a wide range of needs, including preventative and post-operative care for orthopedic and sports-related injuries, treatment for neurologically-related injuries, and rehabilitation services for injured workers. Additionally, the company operates an industrial injury prevention business that provides comprehensive onsite services for employees, encompassing injury prevention, rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

This acquisition marks a significant step for USPH as it continues to fortify its position in the outpatient physical therapy space and expand its service offerings to a broader patient base. As a result of these announcements, the company's shares have moved 1.5% on the market, and are now trading at a price of $81.38. For the full picture, make sure to review U.S. Physical Therapy's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS